Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2646
Abstract: The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID‐19 at high risk of progression to severe disease… read more here.
Keywords: nirmatrelvir ritonavir; risk; ritonavir; drug ... See more keywords
Physiologically‐Based Pharmacokinetic Modeling‐Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID‐19 Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2687
Abstract: Patients with coronavirus disease 2019 (COVID‐19) with cardiovascular diseases who are at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir (Paxlovid). Ritonavir, the booster in nirmatrelvir/ritonavir, modulates multiple drug metabolizing enzymes… read more here.
Keywords: ritonavir paxlovid; based pharmacokinetic; nirmatrelvir ritonavir; physiologically based ... See more keywords
Nirmatrelvir–ritonavir might only be effective in elderly patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28418
Abstract: Nirmatrelvir-ritonavir is an effective and safe oral antiviral drug which have been shown to reduce the risk of progression to severe COVID-191 . It received emergency use authorization from the United States Food and Drug… read more here.
Keywords: elderly patients; nirmatrelvir ritonavir; ritonavir might; might effective ... See more keywords
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28756
Abstract: Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19 patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir is still lacking, despite clinical trials showing their effectiveness compared with matched controls. To compare… read more here.
Keywords: versus nirmatrelvir; azvudine versus; nirmatrelvir ritonavir; ritonavir ... See more keywords
Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Infection"
DOI: 10.1007/s15010-017-1065-5
Abstract: side (previously affected). Her vital signs were stable, with a heart rate oscillating between 72 and 90 beats/min. The rest of the physical examination was unremarkable. She was admitted with the diagnosis of severe bilateral… read more here.
Keywords: sinus bradycardia; ritonavir; beats min; bradycardia ... See more keywords
Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV.
Sign Up to like & getrecommendations! Published in 2020 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2020.119794
Abstract: Human Immunodeficiency Virus (HIV) is a global health concern to which nanomedicine approaches provide opportunities to improve the bioavailability of existing drugs used to treat HIV.In this article, lipid polymer hybrid nanoparticles (LPHNs) were developed… read more here.
Keywords: lipid polymer; hiv; treatment; ritonavir ... See more keywords
National survey study of nirmatrelvir-ritonavir prescribing processes and access barriers during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron surge of the coronavirus disease 2019 (COVID-19) pandemic.
Sign Up to like & getrecommendations! Published in 2023 at "Infection control and hospital epidemiology"
DOI: 10.1017/ice.2023.71
Abstract: In this national survey, we found that individual patient assessments by pharmacists were more common at facilities using centralized prescribing for nirmetralvir-ritonavir (Paxlovid) than decentralized prescribing. Provider discomfort was initially less with centralized prescribing, but… read more here.
Keywords: prescribing; survey study; coronavirus; national survey ... See more keywords
Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemistry"
DOI: 10.1021/acs.biochem.9b00156
Abstract: In a continuing effort to identify structural attributes required for strong binding and potent inhibition of human drug-metabolizing CYP3A4, we designed ten ritonavir-like analogues differing in the side-group stereochemistry, backbone atomic composition, and headgroup spacing.… read more here.
Keywords: group stereochemistry; side group; group; ritonavir ... See more keywords
Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates
Sign Up to like & getrecommendations! Published in 2021 at "Chemical Research in Toxicology"
DOI: 10.1021/acs.chemrestox.1c00028
Abstract: Prophylactic antiretroviral therapy (ART) in HIV infected pregnant mothers and their newborns can dramatically reduce mother-to-child viral transmission and seroconversion in the neonate. The ritonavir-boosted lopinavir regimen, known as Kaletra, has been associated with premature… read more here.
Keywords: inhibition cyp3a7; hiv; ritonavir; therapy ... See more keywords
In vitro inhibition of human UGT isoforms by ritonavir and cobicistat
Sign Up to like & getrecommendations! Published in 2018 at "Xenobiotica"
DOI: 10.1080/00498254.2017.1370655
Abstract: Abstract 1. Ritonavir and cobicistat are pharmacokinetic boosting agents used to increase systemic exposure to other antiretroviral therapies. The manufacturer’s data suggests that cobicistat is a more selective CYP3A4 inhibitor than ritonavir. However, the inhibitory effect… read more here.
Keywords: ritonavir cobicistat; human ugt; ugt isoforms; inhibition human ... See more keywords
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkx246
Abstract: Objectives To assess HIV-1 post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus cobicistat-boosted elvitegravir as a single-tablet regimen (STR), using tenofovir disoproxil fumarate/emtricitabine with both of these therapies. Methods A prospective, open,… read more here.
Keywords: elvitegravir cobicistat; ritonavir; cobicistat; versus ... See more keywords